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Rhombencephalitis 
and Coxsackievirus 
A16 
To the Editor: Hand, foot, and 
mouth  disease  (HFMD)  is  a  com-
mon illness in children and is mainly 
caused by coxsackievirus A16 (CA16) 
and enterovirus 71 (EV71). Although 
its clinical course is usually unevent-
ful and most patients experience a full 
recovery,  serious  neurologic  compli-
cations,  including  encephalitis,  can 
occur  secondarily  to  HFMD  caused 
by EV71. Such neurological compli-
cations occurred during an epidemic 
in  Taiwan  in  1998  (1).  Encephalitis 
caused by EV71 is characterized by 
rhombencephalitis,  which  is  a  com-
bination  of  brainstem  encephalitis 
and cerebellitis. Signs and symptoms 
of  rhombencephalitis  are  irritability, 
myoclonus, ataxia, and cranial nerve 
involvement (1). In contrast to EV71, 
HFMD caused by CA16 is associated 
with  few  neurologic  complications 
with the exception of infrequent asep-
tic meningitis (2). We report a case of 
rhombencephalitis  that  developed  in 
an infant as a complication of HFMD 
caused by CA16.
HFMD  was  diagnosed  in  a  23-
month-old  girl  on  the  basis  of  high 
fever (>40°C, 3 d duration), stomati-
tis, and multiple papules on her palms, 
soles,  and  buttocks.  Her  illness  oc-
curred in the summer of 2007, when 
sentinel surveillance in the region in-
dicated an epidemic of HFMD caused 
by  both  CA16  and  EV71.  She  was 
admitted to our hospital in Fukoka, Ja-
pan, on day 4 of illness because of ab-
normal eye movement, irritability, and 
inability to stand. She had intermittent 
to-and-fro,  horizontal  oscillations  of 
the eyes (ocular flutter). She also had 
truncal and limb ataxia and myoclonus 
in her head and limbs. Brain magnetic 
resonance imaging (MRI) showed T1-
low  and  T2-high  bulbopontine  and 
cerebellar  lesions  around  the  fourth 
ventricle  (Figure).  Peripheral  blood 
showed a mild leukocytosis (13.13 × 
109/L) and a C-reactive protein level 
within  reference  range  (0.9  mg/L). 
Blood  chemistry  results  were  unre-
markable.  Cerebrospinal  fluid  (CSF) 
examination  showed  mononuclear 
pleocytosis (74/µL) with normal pro-
tein  and  glucose  levels.  CA16  was 
isolated from her stool specimen on 
day  4  of  illness.  Based  on  reverse 
transcription–PCR, CSF was negative 
for enterovirus RNA. 
Without  specific  treatment,  our 
patient’s fever resolved on day 5 of 
illness. The myoclonus, ocular flutter, 
and  irritability  subsided  by  day  16, 
when MRI findings returned to nor-
mal. Ataxia disappeared gradually ≈1 
month after onset, and no neurologic 
sequelae occurred. Neutralizing anti-
body titers against CA16 and EV71 
on day 21 of illness were 32 and <8, 
respectively. Based on the sequence 
analysis  of  the  partial  VP1  region 
(876 bp), we classified the patient’s 
CA16 strain phylogenetically as ge-
netic lineage C (3). This lineage was 
identical to lineage 2 (4), which be-
came the dominant circulating strain 
in Asia, including Japan, after the late 
1990s (98.2% identical to the 1018T/
VNM/05  strain  isolated  in  Vietnam 
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in  2005  [GenBank  accession  no. 
AM292441]) (4,5).
The patient’s symptoms of irrita-
bility, ataxia, myoclonus, and ocular 
flutter 3 days after the onset of typi-
cal HFMD manifestations, along with 
CSF mononuclear pleocytosis and the 
lesions  around  the  fourth  ventricle 
shown on MRI, led to the diagnosis 
of rhombencephalitis associated with 
HFMD. Virologic examination, includ-
ing virus isolation and antibody assay, 
suggested that HFMD was caused by 
CA16 but not by EV71, although the 
possibility  that  CA16  infection  was 
coincidental to the rhombencephalitis 
could not be excluded.
Although  rhombencephalitis  can 
be related to various infectious agents 
(6), HFMD complicated by this con-
dition  has  been  exclusively  caused 
by EV71 (1,7,8). In Japan, CA16 and 
EV71  are  consistently  the  2  major 
causative agents of HFMD (9). EV71 
infection is much more frequently as-
sociated with serious neurologic com-
plications and fatalities than is CA16 
(2). Since 1997, several HFMD out-
breaks with multiple cases of severe 
neurologic pathologies have occurred 
in  the  Asia-Pacific  region  including 
Malaysia, Taiwan, and Western Aus-
tralia  (1,7,8).  These  complications 
were  associated  exclusively  with 
EV71.
Why  rhombencephalitis  devel-
oped in our patient with CA16-related 
HFMD  is  unclear.  One  possibility 
is  that  the  CA16  strain  might  have 
acquired  neurovirulence  by  genetic 
recombination  with  EV71;  phyloge-
netic  evidence  supports  the  possible 
occurrence  of  intertypic  recombina-
tion involving EV71 and CA16 (10). 
Through  phylogenetic  analysis  of 
the VP1 sequences, we classified the 
CA16 strain isolated from the patient’s 
stool phylogenetically as genetic lin-
eage C (3), a lineage which was iden-
tical to lineage 2 (4). Genetic recom-
binations among enteroviruses occur 
mainly in noncapsid regions (10). We 
did not conduct phylogenetic analysis 
of  the  noncapsid  regions  of  the  pa-
tient’s CA16 strain because sequence 
data on the regions were very limited. 
Besides the viral factors, host factors, 
such as immune status and environ-
mental  factors,  could  confer  suscep-
tibility to neurologic complications of 
enteroviral infections.
Rhomobencephalitis  associated 
with HFMD developed in this patient 
and was caused by CA16. Therefore, 
neurologic  complications,  including 
rhombencephalitis, should be consid-
ered even when CA16 is the prevalent 
virus causing HFMD.
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Figure.  Axial  T2-weighted  slice  of  brain  by  magnetic  resonance  imaging,  showing 
hyperintensity lesions in the pons and cerebellum around the fourth ventricle.
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Encephalitis in Hill 
and Mountain  
Districts, Nepal
To  the  Editor:  Nepal,  a  land-
locked  country  in  Southeast  Asia 
with  an  estimated  population  of  27 
million,  is  divided  administratively 
into 5 regions; 75 districts comprise 
3 ecological zones that run from east 
to west. Altitude increases from south 
to north: the 20-district Terai plains in 
the south, the hill region in the center 
with  39  districts,  and  the  16-district 
mountain regions in the north. Japa-
nese  encephalitis  (JE)  is  seasonally 
endemic  to  the  Terai  region,  which 
borders  the  northern  India  states  of 
Uttar Pradesh and Bihar. The first out-
break of JE in Nepal was reported in 
1978 from the Terai district of Rupen-
dehi (1). Since then, JE infection has 
been reported in animal reservoirs and 
in humans throughout the Terai region 
(1–5). Although few publications de-
scribe the presence of JE outside the 
Terai, an outbreak of JE in Kathmandu 
valley in the hill region was confirmed 
in 1997 (6), and a 2006 study reported 
JE  endemicity  in  Kathmandu Valley 
(7).  In  recent  years,  the  Ministry  of 
Health  and  Population  in  Nepal  has 
introduced  public  health  interven-
tions,  including  mass  immunization 
campaigns, for JE prevention in these 
known JE-endemic areas.
JE  cases  are  captured  through 
acute  encephalitis  syndrome  (AES) 
surveillance conducted by the govern-
ment of Nepal, with support from the 
World  Health  Organization  (WHO), 
through a national sentinel surveillance 
network. From 2004 through 2006, a 
total  of  108  laboratory-confirmed  JE 
cases were reported from hill or moun-
tain  districts  (excluding  Kathmandu 
Valley). However, travel histories for 
case-patients  were  not  available  for 
these years to determine the origin of 
JE infection. We conducted a study to 
provide evidence of JE endemicity in 
hill  and  mountain  districts  of  Nepal 
(excluding Kathmandu Valley). 
Laboratory-confirmed  JE  case-
patients  identified  in  2007  who  re-
ported  residence  in  1  of  the  52  hill 
or  mountain  districts,  excluding  the 
3  hill  districts  of  the  Kathmandu 
Valley, were followed up by surveil-
lance  medical  officers.  All  patients 
(or next of kin if the patient was de-
ceased  or  unavailable)  were  visited 
at  home  or  contacted  by  telephone 
to confirm their residence and travel 
history during the 30 days before the 
onset of symptoms. Data and sample 
collection  procedures  and  laboratory 
methods used for JE diagnosis were 
as previously reported by Partridge et 
al. (7). Patients were identified by the 
AES  surveillance system  if  patients’ 
symptoms met the case definition for 
AES  adopted from WHO  guidelines 
(www.who.int/vaccines-documents/
DocsPDF06/843.pdf), i.e., acute onset 
of fever and a change in mental status 
(e.g., confusion, disorientation, coma, 
or inability to talk); or if the patient 
experienced a new onset of seizures 
(excluding simple febrile seizures) or 
was identified as having AES, JE, or 
viral encephalitis. The study popula-
tion included any person of any age 
who reported being a resident of 1 of 
the 52 hill or mountain districts (ex-
cluding Kathmandu Valley), who had 
been seen at any AES reporting site 
from January 1 through December 31, 
2007, and who had been confirmed to 
have JE antibody by immunoglobulin 
M capture ELISA on a serum or cere-
brospinal fluid (CSF) specimen.
In 2007, a total of 360 AES cases 
were reported from 40 hill or moun-
tain districts. Of the 344 reported AES 
cases  for  which  diagnostic  samples 
were obtained, 90 (26%) were labora-
tory confirmed as JE from 21 hill and 
3  mountain  districts. Among  labora-
tory confirmed JE cases, CSF samples 
were collected from 13 (14%) patients 
and serum samples from 77 (86%) pa-
tients (Table). The largest number of 
AES and laboratory-confirmed JE cas-
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